Advancing the Development of Treatments for Neurological Disorders
Talking with Billy Dunn, M.D., who is the director of the Division of Neurology Products in CDER’s Office of New Drugs.
FDA recently published five guidances for industry related to neurological conditions. The release of these guidances was noteworthy for many reasons and reflects a renewed commitment to describing the agency’s thinking and providing advice on conducting clinical studies in specific neurological indications. Billy Dunn, who is the director of CDER’s Division of Neurology Products, discusses the guidances and why they are significant.
For more information, please visit: CDER Conversations.